Pulmonary hypertension in majority countries: opportunities amidst challenges.


Journal

Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765

Informations de publication

Date de publication:
09 2020
Historique:
pubmed: 24 7 2020
medline: 27 4 2021
entrez: 24 7 2020
Statut: ppublish

Résumé

Pulmonary hypertension is a deadly disease, the causes of which vary between geographical regions. Eighty four percentage of the world's population lives in majority countries (also called low-income and middle-income countries), yet data on pulmonary hypertension in these settings are proportionally scarce. This article provides a review of pulmonary hypertension in majority countries, focusing in detail on the most common causes in these regions, and highlights contextual challenges faced. Epidemiological data confirms a complex and overlapping array of causes, with pulmonary hypertension because of conditions such as rheumatic heart disease, HIV, schistosomiasis, chronic lung disease and sickle cell disease. Delayed pulmonary hypertension diagnosis remains a concern and is ascribed to a lack of resources and lack of pulmonary hypertension awareness by health professionals. Pulmonary hypertension diagnosis is frequently considered once signs of right heart failure emerge, while echocardiography and right heart catheterization are unavailable in many settings. Accurate data on the prevalence of pulmonary hypertension in many of these regions are needed and could be achieved by establishing and frequent review of national databases where the incident and prevalent pulmonary hypertension cases are captured. There is urgent need for pulmonary hypertension advocacy among clinicians in the primary, secondary and tertiary healthcare sectors of majority countries, and validated noninvasive diagnostic algorithms are needed. Increased awareness and early diagnosis are likely to improve outcomes of pulmonary hypertension patients in these regions, and potentially stimulate locally relevant research.

Identifiants

pubmed: 32701672
doi: 10.1097/MCP.0000000000000702
pii: 00063198-202009000-00002
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

373-383

Références

Allwood BW, Maarman GJ, Kyriakakis CG, Doubell AF. Postpulmonary tuberculosis complications in South Africa and a potential link with pulmonary hypertension: premise for clinical and scientific investigations. S Afr Med J 2018; 108:12339.
Gordeuk VR, Castro OL, Machado RF. Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood 2016; 127:820–828.
Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53:1801915.
Mickael CS, Graham BB. The role of type 2 inflammation in schistosoma-induced pulmonary hypertension. Front Immunol 2019; 10:27.
Thienemann F, Dzudie A, Mocumbi AO, et al. The causes, treatment, and outcome of pulmonary hypertension in Africa: insights from the Pan African Pulmonary Hypertension Cohort (PAPUCO) Registry. Int J Cardiol 2016; 221:205–211.
Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endor. Eur Heart J 2016; 37:67–119.
Dzudie A, Dzekem BS, Ojji DB, et al. Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa. Cardiovasc Diagn Ther 2019; 10:316–324.
Thienemann F, Dzudie A, Mocumbi AO, et al. Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa. BMJ Open 2014; 4:e005950.
Rich JD, Rich S. Clinical diagnosis of pulmonary hypertension. Circulation 2014; 130:1820–1830.
Mocumbi AO, Thienemann F, Sliwa K. A global perspective on the epidemiology of pulmonary hypertension. Can J Cardiol 2015; 31:375–381.
Essop MR, Galie N, Badesch DB, et al. Management of pulmonary hypertension. S Afr Med J 2015; 105:437–439.
Zhang HS, Liu Q, Piao CM, et al. Genotypes and phenotypes of Chinese pediatric patients with idiopathic and heritable pulmonary arterial hypertension – a single-center study. Can J Cardiol 2019; 35:1851–1856.
Zhang R, Dai LZ, Xie WP, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era. Chest 2011; 140:301–309.
Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007; 132:373–379.
Iranmehr A, Stobdan T, Zhou D, et al. Novel insight into the genetic basis of high-altitude pulmonary hypertension in Kyrgyz highlanders. Eur J Hum Genet 2019; 27:150–159.
Abraham MT, Cherian G. Primary pulmonary hypertension in India. Indian Heart J 1981; 33:5–7.
Kinare SG, Deshpande J. Primary pulmonary hypertension in India (autopsy study of 26 cases). Indian Heart J 1987; 39:9–16.
Chopra S, Badyal DK, Baby PC, Cherian D. Pulmonary arterial hypertension: advances in pathophysiology and management. Indian J Pharmacol 2012; 44:4–11.
Bansal S, Utpat K, Desai U, Joshi J. Clinical profile of pulmonary hypertension at a tertiary care centre, India. Eur Respir J 2017; 50: (Suppl 61): A2439.
Negi PC, Marwaha R, Asotra S, et al. Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley – a high altitude region in Himachal Pradesh, India. High Alt Med Biol 2014; 15:504–510.
Harikrishnan S, Sanjay G, Ashishkumar M, et al. Pulmonary Hypertension Registry of Kerala (PROKERALA) – rationale, design and methods. Indian Heart J 2016; 68:709–715.
Gupta KK, Roy B, Chaudhary SC, et al. Prevalence of pulmonary artery hypertension in patients of chronic obstructive pulmonary disease and its correlation with stages of chronic obstructive pulmonary disease, exercising capacity, and quality of life. J Fam Med Prim Care 2018; 7:53–57.
Vinayak M, Sharma A, Sinha DP. Assessment of prognostic factors and natural history of idiopathic pulmonary arterial hypertension in Eastern India. J Assoc Physicians India 2019; 67:57–61.
Lopes AA, Bandeira AP, Flores PC, Tavares Santana MV. Pulmonary hypertension in Latin America: pulmonary vascular disease: the global perspective. Chest 2010; 137: (6 Suppl.): 78S–84S.
Alves JL, Gavilanes F, Jardim C, et al. Pulmonary arterial hypertension in the Southern Hemisphere results from a registry of incident Brazilian cases. Chest 2015; 147:495–501.
Valverde AB, Soares JM, Viana KP, et al. Pulmonary arterial hypertension in Latin America: epidemiological data from local studies. BMC Pulm Med 2018; 18:106.
Grimminger J, Richter M, Tello K, et al. Thin air resulting in high pressure: mountain sickness and hypoxia-induced pulmonary hypertension. Can Respir J 2017; 2017:8381653.
Eichstaedt CA, Mairbaurl H, Song J, et al. Genetic predisposition to high-altitude pulmonary edema. High Alt Med Biol 2020; 21:28–36.
Wilkins MR, Ghofrani HA, Weissmann N, et al. Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation 2015; 131:582–590.
Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Resp Med 2016; 4:306–322.
Dzudie A, Dzekem BS, Ojji DB, et al. Pulmonary hypertension in low- and middle-income countries with focus on sub-Saharan Africa. Cardiovasc Diagn Ther 2019; 10:316–324.
Dzudie A, Kengne AP, Thienemann F, Sliwa K. Predictors of hospitalisations for heart failure and mortality in patients with pulmonary hypertension associated with left heart disease: a systematic review. BMJ Open 2014; 4:e004843.
Thienemann F, Dzudie A, Mocumbi AO, et al. The causes, treatment, and outcome of pulmonary hypertension in Africa: insights from the Pan African Pulmonary Hypertension Cohort (PAPUCO) Registry. Int J Cardiol 2016; 221:205–211.
Dzudie A, Dzekem BS, Tchoumi CT, et al. Pulmonary hypertension as seen in a rural area in sub-Saharan Africa: high prevalence, late clinical presentation and a high short-term mortality rate during follow up. Cardiovasc J Afr 2018; 29:208–212.
Bigna JJ, Noubiap JJ, Nansseu JR, Aminde LN. Prevalence and etiologies of pulmonary hypertension in Africa: a systematic review and meta-analysis. BMC Pulm Med 2017; 17:183.
Chillo P, Bakari M, Lwakatare J. Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania. Cardiovasc J Afr 2012; 23:90–97.
Menanga AP, Ngomseu CK, Jingi AM, et al. Patterns of cardiovascular disease in a group of HIV-infected adults in Yaoundé, Cameroon. Cardiovasc Diagn Ther 2015; 5:420–427.
Stewart S, Mocumbi AO, Carrington MJ, et al. A not-so-rare form of heart failure in urban black Africans: pathways to right heart failure in the Heart of Soweto Study cohort. Eur J Heart Fail 2011; 13:1070–1077.
Papamatheakis DG, Mocumbi AO, Kim NH, Mandel J. Schistosomiasis-associated pulmonary hypertension. Pulm Circ 2014; 4:596–611.
Statistics South Africa (SSA). Mid-year population estimates 2019. Pretoria, South Africa: Statistics South Africa (SSA); 2018.
Maarman GJ. Pulmonary arterial hypertension and the potential roles of metallothioneins: a focused review. Life Sci 2018; 214:77–83.
Maarman GJ. Making a case for metallothioneins conferring cardioprotection in pulmonary hypertension. Med Hypotheses 2020; 137:109572.
Maarman GJ, Schulz R, Sliwa K, et al. Novel putative pharmacological therapies to protect the right ventricle in pulmonary hypertension: a review of current literature. Br J Pharmacol 2017; 174:497–511.
UNAIDS. UNAIDS factsheet: global HIV statistics 2019. Geneva, Switzerland: UNAIDS; 2019.
Bigna JJ, Nansseu JR, Noubiap JJ. Pulmonary hypertension in the global population of adolescents and adults living with HIV: a systematic review and meta-analysis. Sci Rep 2019; 9:7837.
Sitbon O, Lascoux-Combe C, Delfraissy J-F, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 2008; 177:108–113.
Howard LS. Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease. Eur Respir Rev 2011; 20:236–242.
Jarrett H, Barnett C. HIV-associated pulmonary hypertension. Curr Opin HIV AIDS 2017; 12:566–571.
Degano B, Yaici A, Le Pavec J, et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J 2009; 33:92–98.
Butrous G. Human Immunodeficiency virus-associated pulmonary arterial hypertension considerations for pulmonary vascular diseases in the developing world. Circulation 2015; 131:1361–1370.
Pal J, Sen K, Sarkar G, et al. Effect of antiretroviral therapy on pulmonary hypertension in HIV patients. J Indian Med Assoc 2013; 111:845–849.
Pugliese A, Isnardi D, Saini A, et al. Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J Infect 2000; 40:282–284.
Zuber JP, Calmy A, Evison JM, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004; 38:1178–1185.
Wang X, Chai H, Lin PH, et al. Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other antihuman immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 2009; 174:771–781.
Gary-Bobo G, Houssaini A, Amsellem V, et al. Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation 2010; 122:1937–1947.
Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002; 16:1568–1569.
Schumacher YO, Zdebik A, Huonker M, Kreisel W. Sildenafil in HIV-related pulmonary hypertension. AIDS 2001; 15:1747–1748.
Barbaro G, Lucchini A, Pellicelli AM, et al. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart 2006; 92:1164–1166.
Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010–3019.
Peacock AJ, Zamboni W, Vizza CD. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. Curr Med Res Opin 2015; 31:1793–1807.
Kern RM, Seethamraju H, Blanc PD, et al. The feasibility of lung transplantation in HIV-seropositive patients. Ann Am Thorac Soc 2014; 11:882–889.
Deol AK, Fleming FM, Calvo-Urbano B, et al. Schistosomiasis – assessing progress toward the 2020 and 2025 global goals. N Engl J Med 2019; 381:2519–2528.
Stothard JR, Campbell SJ, Osei-Atweneboana MY, et al. Towards interruption of schistosomiasis transmission in sub-Saharan Africa: developing an appropriate environmental surveillance framework to guide and to support ’end game’ interventions. Infect Dis Poverty 2017; 6:10.
World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva, Switzerland: World Health Organization; 2012.
WHO. World Health Organization progress report 2001–2011 and strategic plan 2012–2020. Geneva, Switzerland: WHO; 2013.
Collaborators GBDD Injury I Prevalence. Global Regional and National Incidence, prevalence and years lived with disability for 354 diseases and injuries in 195 countries and territories 2017: a systematic analysis for the Global Burden of Disease Study. Lancet 2018; 392:1789–1858.
Hotez PJ, Alvarado M, Basanez MG, et al. The Global Burden of Disease Study 2010: interpretation and Implications for the Neglected Tropical Diseases. PLoS Negl Trop Dis 2014; 8:e2865.
World Health Organization. Schistosomiasis: key facts. Geneva, Switzerland: World Health Organization; 2019.
Magaisa K, Taylor M, Kjetland EF, Naidoo PJ. A review of the control of schistosomiasis in South Africa. S Afr J Sci 2015; 111:32–37.
Gavilanes F, Fernandes CJC, Souza R. Pulmonary arterial hypertension in schistosomiasis. Curr Opin Pulm Med 2016; 22:408–414.
Papamatheakis DG, Mocumbi AOH, Kim NH, Mandel J. Schistosomiasis-associated pulmonary hypertension. Pulm Circ 2014; 4:596–611.
Ross AGP, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002; 346:1212–1220.
Butrous G. Schistosome infection and its effect on pulmonary circulation. Glob Cardiol Sci Pract 2019; 2019:5.
Andrade ZA, Andrade SG. Pathogenesis of schistosomal pulmonary arteritis. Am J Trop Med Hyg 1970; 19:305–310.
Kolosionek E, King J, Rollinson D, et al. Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: detailed study. Pulm Circ 2013; 3:356–362.
Knafl D, Gerges C, King CH, et al. Schistosomiasis-associated pulmonary arterial hypertension: a systematic review. Eur Respir Rev 2020; 29:
Piscoya Roncal CG, Mendes AA, Muniz MTC, et al. Schistosomiasis-associated pulmonary arterial hypertension: survival in endemic area in Brazil. Int J Cardiol Heart Vasc 2019; 25:100373.
Butrous G. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: schistosomiasis and pulmonary arterial hypertension. Ann Thorac Med 2014; 9: (Suppl 1): S38–S41.
de Almeida MA, Andrade ZA. Effect of chemotherapy on experimental pulmonary schistosomiasis. Am J Trop Med Hyg 1983; 32:1049–1054.
Fernandes CJC, Piloto B, Castro M, et al. Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. Eur Respir J 2018; 51:1800307.
Vachiery JL, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018; 51:
Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5:685–694.
Zuhlke L, Engel ME, Karthikeyan G, et al. Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur Heart J 2015; 36:1115–1122.
Vachiéry J-L, Tedford RJ, Rosenkranz S, et al. Pulmonary hypertension due to left heart disease. Eur Respir J 2019; 53:1801897.
Bermejo J, Yotti R, Garcia-Orta R, et al. Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial. Eur Heart J 2018; 39:1255–1264.
Vachiéry J-L, Delcroix M, Al-Hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 2018; 51:1701886.
WHO. World Health Organisation chronic obstructive pulmonary disease (COPD) fact sheet. Geneva, Switzerland: WHO; 2020.
Gold, Inc., Global Initiative for Chronic Obstructive Lung Inc. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2020 report. 2020.
WHO. World Health Organisation chronic obstructive pulmonary disease (COPD): key facts. Geneva, Switzerland: WHO; 2017.
Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 2019; 53:
Sakao S, Voelkel NF, Tatsumi K. The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations. Eur Respir Rev 2014; 23:350–355.
Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration 2013; 86:76–85.
Caballero A, Torres-Duque CA, Jaramillo C, et al. Prevalence of COPD in five Colombian cities situated at low, medium, and high altitude (PREPOCOL study). Chest 2008; 133:343–349.
Lam K-bH, Jiang CQ, Jordan RE, et al. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest 2010; 137:593–600.
Menezes AMB, Hallal PC, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007; 30:1180–1185.
Amaral AFS, Coton S, Kato B, et al. Tuberculosis associates with both airflow obstruction and low lung function: BOLD results. Eur Respir J 2015; 46:1104–1112.
Magitta NWF, Walker RW, Apte KK, et al. Prevalence, risk factors and clinical correlates of COPD in a rural setting in Tanzania. Eur Respir J 2018; 51:1700182.
Byrne AL, Marais BJ, Mitnick CD, et al. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis 2015; 32:138–146.
Marjani M, Baghaei P, Malelzmohammad M, et al. Effect of pulmonary hypertension on outcome of pulmonary tuberculosis. Braz J Infect Dis 2014; 18:487–490.
Romanowski K, Baumann B, Basham CA, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19:1129–1137.
WHO. Fact sheets on tuberculosis. Geneva, Switzerland: WHO; 2020.
Simonneau G, Torbicki A, Dorfmuller P, Kim N. The pathophysiology of chronic thromboembolic pulmonary hypertension. Eur Respir Rev 2017; 26:
Ogawa A, Satoh T, Fukuda T, et al. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: results of a multicenter registry. Circ Cardiovasc Qual Outcomes 2017; 10:
Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011; 124:1973–1981.
Villaquiran C, Duenas R, Torres A. Diagnosis and Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension in Five Reference Centers In Bogota – Colombia, at 2.640 Meters Above Sea Level. C60 chronic thromboembolic pulmonary hypertension. 2015; A4847-A.
Yu Y, Yang L, Zhang Y, et al. Incidence and risk factors of chronic thromboembolic pulmonary hypertension in patients with diagnosis of pulmonary embolism for the first time in real world. Clin Respir J 2018; 12:2551–2558.
Tiede H, Hoeper MM, Richter M, et al. Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): an epidemiological analysis. Eur Respir J 2014; 44: (Suppl 58): 2326.
Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008; 359:2254–2265.
Aliyu ZY, Gordeuk V, Sachdev V, et al. Prevalence and risk factors for pulmonary artery systolic hypertension among sickle cell disease patients in Nigeria. Am J Hematol 2008; 83:485–490.
Fonseca GHH, Souza R, Salemi VMC, et al. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J 2012; 39:112–118.
Mehari A, Alam S, Tian X, et al. Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med 2013; 187:840–847.
Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary hypertension in sickle cell disease. N Engl J Med 2011; 365:44–53.
Aliyu ZY, Kato GJ, Taylor 6th J, et al. Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. Am J Hematol 2008; 83:63–70.
Musa BM, Galadanci NA, Coker M, et al. The global burden of pulmonary hypertension in sickle cell disease: a systematic review and meta-analysis. Ann Hematol 2016; 95:1757–1764.
Castro O, Hoque M, Brown BD. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. Blood 2003; 101:1257–1261.
Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med 2014; 189:727–740.
Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood 2011; 118:855–864.
Bank TW. World populations 2020 [Available from: https://datacatalog.worldbank.org/dataset/population-estimates-and-projections]. [Accessed 19 May, 2020].
Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016; 4:306–322.
Rich S, Haworth SG, Hassoun PM, Yacoub MH. Pulmonary hypertension: the unaddressed global health burden. Lancet Respir Med 2018; 6:577–579.
Marangou J, Beaton A, Aliku TO, et al. Echocardiography in indigenous populations and resource poor settings. Heart Lung Circ 2019; 28:1427–1435.
McGoon MD, Ferrari P, Armstrong I, et al. The importance of patient perspectives in pulmonary hypertension. Eur Respir J 2019; 53:

Auteurs

Gerald J Maarman (GJ)

Division of Medical Physiology, CARMA: Centre for Cardio-Metabolic Research in Africa.

Jane Shaw (J)

Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Brian Allwood (B)

Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH